Patents Represented by Attorney, Agent or Law Firm Mary M. Krinsky
  • Patent number: 6548042
    Abstract: The present invention provides a pharmaceutical compound, or pharmaceutically acceptable salt thereof, for use in medicine, wherein said compound is of formula I wherein R is a pharmaceutically active moiety; Ar is an aromatic moiety; X is a linker group; and Y is a moiety comprising two phosphonate groups. Further aspects of the invention relate to a method for palliative and curative treatment of bone disorders and cancer related disorders, such as breast cancer.
    Type: Grant
    Filed: July 9, 2001
    Date of Patent: April 15, 2003
    Inventors: Erik {haeck over (A)}rstad, Lars Skattebøl
  • Patent number: 6541478
    Abstract: Nicotine dependency is treated by administration of an opioid antagonist. In some embodiments, rapid or ultra rapid detoxification techniques include using a combination of an effective amount of an opioid antagonist such as nalmefene, naloxone or naltrexone or a mixture of any one of these, and either clonidine or related compounds either while awake, or while under sedation or anesthesia, followed by continued administration of an effective amount of an opioid antagonist with or without agents that enhance nicotine dependency treatment.
    Type: Grant
    Filed: September 16, 1999
    Date of Patent: April 1, 2003
    Assignee: Yale University
    Inventors: Stephanie O'Malley, Boris Meandzija, Suchitra Krishnan-Sarin
  • Patent number: 6500857
    Abstract: Aging and sagging subcutaneous muscles are treated by first applying a composition containing at least one acetylcholine precursor and/or at least one compound exhibiting catecholamine activity to the overlying skin area, and then electronically stimulating the overlying skin area using electrical pulses in amounts sufficient to cause the subcutaneous muscles to contract. Preferred compositions contain from about 1% to about 10%, more narrowly from about 0.25% to about 5% by weight of an alkanolamine such as dimethylaminoethanol, the calcium salt of 2-aminoethanol phosphate or mixtures thereof and about from about 1% to about 10%, more narrowly from about 1% to 5% by weight of a compound exhibiting catecholamine activity such as tyrosine. Preferred electronic muscle stimulating devices deliver electrical pulses via electrodes in the fingertips of a compact device that fits on the hand.
    Type: Grant
    Filed: August 16, 2001
    Date of Patent: December 31, 2002
    Inventor: Nicholas V. Perricone
  • Patent number: 6492131
    Abstract: A protein with canonical lysyl-tRNA synthetase activity was purified from Methanococcus maripaludis, cloned, and sequenced. The predicted amino acid sequence of the enzyme indicated a novel class I polypeptide structurally unrelated to class II lysyl-tRNA synthetase reported in eubacteria, eukaryotes, and the Crenarchaeote Sulfobus solfataricus. A similar class I polypeptide was isolated from Borrelia burgdorferi, the causative agent of Lyme disease, and an open reading frame encoding a class I-type lysyl-tRNA synthetase was identified in the genome of Treponema pallidum, the causative agent of syphilis. The B. burdorferi gene encoding tRNALysl was cloned and used to make tRNA in vitro. The fundamental difference between pathogen and host in an essential enzyme suggests that class I-type lysyl-tRNA synthetase provides a target for the development of medical and veterinary therapeutics and diagnostics for Borrelia and other microorganism infections.
    Type: Grant
    Filed: March 10, 2000
    Date of Patent: December 10, 2002
    Assignee: Yale University
    Inventors: Dieter Söll, Michael Ibba
  • Patent number: 6437004
    Abstract: Free radical-scavenging olive oil polyphenols are topically applied to treat skin damage, such as contact dermatitis (particularly diaper area dermatitis), atopic dermatitis, xerosis, eczema (including severe hand and foot eczema), rosacea, seborrhea, psoriasis, thermal and radiation burns, other types of skin inflammation, and aging. Typical compositions contain from about 0.25% to about 10% of a polyphenol preparation obtained from olive oil.
    Type: Grant
    Filed: May 7, 2001
    Date of Patent: August 20, 2002
    Inventor: Nicholas V. Perricone
  • Patent number: 6429018
    Abstract: A prenatal screening method for Down's syndrome involves assaying for hyperglycosylated gonadotropin in biological test samples such as urine, plasma or serum obtained from pregnant women. Hyperglycosylated gonadotropin comprises a variant population of chorionic gonadotropin, chorionic gonadotropin-free &bgr;-subunit, &bgr;-core fragment, and/or free &agr;-subunit exhibiting differences in the carbohydrate content from what is observed in samples obtained from pregnant women carrying normal fetuses. Qualitative or quantitative observation of differences in the carbohydrate content of the hyperglycosylated gonadotropin population from corresponding control samples containing a normal gonadotropin population, or direct observation of the variant species seen in Down's syndrome, indicates that the woman's fetus has Down's syndrome. Typical screens involve carbohydrate analyses, immunoassays, or combinations of these methods.
    Type: Grant
    Filed: November 29, 1999
    Date of Patent: August 6, 2002
    Assignee: Yale University
    Inventors: Laurence A. Cole, Andrew Kardana
  • Patent number: 6417226
    Abstract: Skin whitening compositions contain &agr;-hydroxytetronic acid or a &agr;-hydroxy tetronic derivative, and, in some cases, hydroquinone, an &agr;-hydroxy acid such as glycolic acid, and a fatty acid ester of ascorbic acid such as ascorbyl palmitate.
    Type: Grant
    Filed: December 12, 2000
    Date of Patent: July 9, 2002
    Inventor: Nicholas V. Perricone
  • Patent number: 6365623
    Abstract: Active acne and acneiform scars are treated by topical application of a composition containing lipoic acid and/or a lipoic acid derivative such as dihydrolipoic acid, a lipoic or dihydrolipoic acid ester, a lipoic or dihydrolipoic acid amide, a lipoic or dihydrolipoic acid salt, and mixtures of any of these to reduce erythema, pore size, and scarring. Topical application of lipoic acid and/or a lipoic acid derivatives are advantageously used with at least one adjunct ingredient such as a retinoid, an antibiotic, or benzoyl peroxide conventionally used for acne, alone or in combination with dimethylaminoalcohol, an &agr;-hydroxy acid such as glycolic acid, a tyrosine, tocotrienol, and/or a fatty acid ester of ascorbic acid. One preferred embodiment contains a combination of lipoic acid, an &agr;-hydroxy acid, and dimethylaminoalcohol.
    Type: Grant
    Filed: December 30, 1999
    Date of Patent: April 2, 2002
    Inventor: Nicholas V. Perricone
  • Patent number: 6319942
    Abstract: Cutaneous scars are reduced by the topical application of compositions containing an alkanolamine such as ethylaminoethanol, methylaminoethanol, dimethylaminoethanol, isopropanolamine, triethanolamine, isopropanoldimethylamine, ethylethanolamine, 2-butanolamine, choline, serine, and mixtures thereof. Compositions may be applied directly to scar tissue, or embedded in linaments held against the scars. Dimethylaminoethanol in amounts ranging from about 0.1% to about 10% by weight of the total composition is particularly preferred. Adjunct ingredients such as lipoic acid, tyrosine, ascorbyl palmitate, and glycolic acid may be added to scar-reducing formulations, and are desirable in many embodiments.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: November 20, 2001
    Inventor: Nicholas V. Perricone
  • Patent number: 6296861
    Abstract: A synergistic combination of conjugated linoleic acid and fatty acid esters of ascorbic acid is topically applied to treat skin damage, such as contact dermatitis, atopic dermatitis, xerosis, eczema, rosacea, seborrhea, psoriasis, thermal and radiation burns, other types of skin inflammation, and aging. Typical compositions contain from about 1% to about 25% by weight of a CLA preparation containing 9,11-octadecadienoic acid and 10,12-octadecadienoic acid, and from about 0.5% to about 15% by weight of a saturated fatty acid ester of ascorbic acid such as ascorbyl palmitate.
    Type: Grant
    Filed: May 2, 2000
    Date of Patent: October 2, 2001
    Inventor: Nicholas V. Perricone
  • Patent number: 6287563
    Abstract: There is disclosed the use, as an agent in the treatment or the prevention of an autoimmune disease, of: (i) an agent having GM-1 binding activity, other than Ctx or Etx, or the B subunits of Ctx and Etx; or (ii) an agent having an effect on GM-1 mediated intracellular signalling events, but no GM-1 binding activity. These agents may also be used in the treatment of human T cell leukaemia, in the prevention of transplant rejection or GVHD or in a vaccination method for vaccinating a mammalian subject.
    Type: Grant
    Filed: December 29, 1997
    Date of Patent: September 11, 2001
    Inventors: Neil Andrew Williams, Timothy Raymond Hirst, Toufic Osman Nashar
  • Patent number: 6274633
    Abstract: The present invention relates to the use of xenon as an NMDA antagonist. In particular, the invention relates to a method of treatment comprising modulating the activity of an NMDA receptor in a mammal, the method comprising modulating the activity of the NMDA receptor by administering to the mammal a therapeutically effective amount of xenon. In a further aspect, the invention provides a process for the preparation of a pharmaceutical composition suitable for modulating the activity of an NMDA receptor.
    Type: Grant
    Filed: August 23, 1999
    Date of Patent: August 14, 2001
    Assignee: Imperial College of Science, Technology, and Medicine
    Inventors: Nicholas Peter Franks, Mervyn Maze
  • Patent number: 6252045
    Abstract: The gene for occludin, an integral transmembrane protein specifically associated with tight junctions that functions in forming intercellular seal, is cloned, characterized, and sequenced, and the polypeptide sequence determined. Drug delivery is enhanced by administering an effective amount of occludin inhibitors. These include peptides or antibodies that interact with occludin or occludin receptors. Also included are occludin antagonists, occludin receptor components, and mixtures thereof. In some embodiments, analogues of occludin surface loops that inhibit adhesion and/or barrier properties are employed. Administration can be local or systemic; local administration in a pharmaceutically acceptable carrier is preferred in some embodiments.
    Type: Grant
    Filed: September 15, 1998
    Date of Patent: June 26, 2001
    Assignee: Yale University
    Inventors: James M. Anderson, Christina M. Van Itallie
  • Patent number: 6218673
    Abstract: An optical scanner gives three dimensional dosimetric data by scanning, with at least one light beam, a translucent medium exhibiting optical properties which change upon receipt of radiant energy representing a dose distribution of the energy. At least one detector is employed to gather data indicative of changes in the optical properties of the medium after scanning from multiple directions to provide a representation of the optical properties in sections through the medium. Typical optical properties measured include optical density, light scattering, emitted light intensities, and combinations thereof.
    Type: Grant
    Filed: September 5, 1997
    Date of Patent: April 17, 2001
    Assignee: Yale University
    Inventors: John C. Gore, Marek J. Maryanski, Robert J. Schulz
  • Patent number: 6191121
    Abstract: Polyenylphosphatidylcholine is topically applied to treat skin damage, such as contact dermatitis (particularly diaper area dermatitis), atopic dermatitis, xerosis, eczema (including severe hand and foot eczema), rosacea, seborrhea, psoriasis, thermal and radiation burns, other types of skin inflammation, and aging. Typical compositions contain from about 0.25% to about 10% of a polyenylphosphatidylcholine preparation obtained from natural sources such as soybean oil which contains at least about 25% by weight, preferably about 40% or more, dilinoeoylphosphatidylcholine.
    Type: Grant
    Filed: April 6, 2000
    Date of Patent: February 20, 2001
    Inventor: Nicholas V. Perricone
  • Patent number: 6140470
    Abstract: Human monoclonal anti-tumor antibodies are isolated from fusion phage single-chain Fv and V.sub.H antibody libraries constructed from the peripheral blood lymphocytes of immunized cancer patients. Antibodies that bind to tumor cells of the same kind as the patient's are selected, and antibodies that also bind to a human normal cell type are removed. The remaining fusion phage antibodies are cloned and then are tested for binding to at least two normal human cell types. Antibodies that fail to bind to the normal cells are further tested for binding to a panel of tumor cells, typically including the original tumor type and several related and unrelated tumors. Human monoclonal antibodies that bind specifically to the original tumor or also to some other tumors, or that bind to the original tumor and cells from the same developmental lineage, are obtained and sequenced. The selected antibodies can be used to design molecules which are potentially useful for various diagnostic and therapeutic purposes.
    Type: Grant
    Filed: April 27, 1998
    Date of Patent: October 31, 2000
    Assignee: Yale University
    Inventors: Alan Garen, Xiaohang Cai
  • Patent number: 6036958
    Abstract: A potent and specific inhibitor of thrombin is purified from salivary gland extracts of the tsetse fly, Glossina morsitans morsitans. The inhibitor has a molecular weight of 3530 Daltons as determined by laser desorption mass spectroscopy. The inhibitor is useful as an anticoagulant and an inhibitor of platelet aggregation and in pharmaceutical and immunogenic compositions.
    Type: Grant
    Filed: July 15, 1999
    Date of Patent: March 14, 2000
    Assignee: Yale University
    Inventors: Michael Cappello, Serap Aksoy
  • Patent number: D459478
    Type: Grant
    Filed: September 24, 2001
    Date of Patent: June 25, 2002
    Inventor: Nicholas V. Perricone
  • Patent number: D459479
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: June 25, 2002
    Inventor: Nicholas V. Perricone
  • Patent number: D459816
    Type: Grant
    Filed: September 21, 2001
    Date of Patent: July 2, 2002
    Inventor: Nicholas V. Perricone